While Arcutis Biotherapeutics Inc has overperformed by 0.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT rose by 264.11%, with highs and lows ranging from $15.79 to $3.11, whereas the simple moving average jumped by 46.79% in the last 200 days.
On December 30, 2024, H.C. Wainwright started tracking Arcutis Biotherapeutics Inc (NASDAQ: ARQT) recommending Buy. A report published by Jefferies on August 28, 2024, Initiated its previous ‘Buy’ rating for ARQT. Mizuho also Upgraded ARQT shares as ‘Buy’, setting a target price of $8 on the company’s shares in a report dated January 03, 2024. Mizuho October 26, 2023d the rating to Neutral on October 26, 2023, and set its price target from $57 to $4. Goldman October 13, 2023d its ‘Buy’ rating to ‘Neutral’ for ARQT, as published in its report on October 13, 2023. Needham’s report from September 07, 2022 suggests a price prediction of $46 for ARQT shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Arcutis Biotherapeutics Inc (ARQT)
Further, the quarter-over-quarter increase in sales is 17.44%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Arcutis Biotherapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -192.31% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.38, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.03M can be a very valuable indicator of volatility for ARQT stock. On a monthly basis, the volatility of the stock is set at 7.74%, whereas on a weekly basis, it is put at 5.61%, with a gain of 2.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.12, showing growth from the present price of $14.71, which can serve as yet another indication of whether ARQT is worth investing in or should be passed over.
How Do You Analyze Arcutis Biotherapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.03%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 103.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARQT shares are owned by institutional investors to the tune of 103.05% at present.
